Day One Biopharmaceuticals (NASDAQ:DAWN) is a clinical-stage biotechnology company dedicated to developing precision therapies for patients with solid tumors. The company’s research focuses on designing small molecules that target key drivers of cancer growth and survival, including hormone receptors and cell cycle regulators. Its lead candidate, camizestrant, is an oral selective estrogen receptor degrader (SERD) currently in late-stage development for the treatment of estrogen receptor-positive, HER2-negative advanced breast cancer.
Beyond its lead program, Day One leverages a proprietary discovery platform to advance additional candidates across multiple oncology targets. Early-stage assets include novel molecules aimed at disrupting oncogenic signaling and DNA damage repair pathways. The company’s pipeline strategy emphasizes differentiated mechanisms of action designed to address areas of high unmet medical need and to overcome resistance to existing therapies.
Founded in 2018 and headquartered in San Francisco, Day One Biopharmaceuticals completed its initial public offering in mid-2021. The company maintains research operations in San Diego and supports clinical development through collaboration with trial sites across North America and Europe. This geographic footprint enables Day One to enroll a diverse patient population and to expedite regulatory interactions with health authorities in key markets.
Day One’s leadership team is led by Chief Executive Officer David Meek, a seasoned biotech executive with more than two decades of experience in oncology drug development and commercialization. The management team also includes veterans from leading pharmaceutical and biotechnology companies, bringing deep expertise in clinical operations, regulatory affairs, and global commercial planning. Under this guidance, Day One is positioned to advance its pipeline toward potential regulatory approval and to deliver new treatment options for cancer patients.
AI Generated. May Contain Errors.
Free DAWN Stock Alerts